THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Directorate Change […]
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma’s lead asset, XF-73, well positioned to address the global threat of anti-microbial resistance highlighted in new UK government report Brighton, United Kingdom – 24 October 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address […]
Destiny Pharma plc (“Destiny Pharma” or the “Company”) A series of videos and explainer documents launched, focusing on cutting-edge R&D taking place in UK biotech companies, including Destiny Pharma Destiny Pharma has been chosen to exemplify the UK’s leading status in antimicrobial resistance research Brighton, United Kingdom – 19 October 2018 – Destiny Pharma (AIM: DEST), […]
Valencia, Calif., USA, and Melbourne, Australia, 18 October 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received the first commercial sales orders from U.S. burn centers for the RECELL® Autologous Cell Harvesting Device (RECELL® System) and has commenced commercial shipment of the product. The U.S. […]
Tuesday, October 16, 2018 4:10 pm EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously announced underwritten public offering. Gross proceeds to AmpliPhi from […]
Valencia, Calif., USA, and Melbourne, Australia, 15 October 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that a medical education symposium on the use of the RECELL® Autologous Cell Harvesting Device (RECELL® System) was held at the U.S. Midwest Region Burn Conference in Minneapolis. The symposium was led […]
ARECOR LIMITED (“Arecor” or “the Company”) ARECOR JOINS ELITE INVESTOR ROADSHOW TO CHINA “Arecor has joined the London Stock Exchange Group’s latest ELITE mission to China for aspiring companies and will participate in investor roadshow events, in Shenzhen and Hong Kong, between 15th – 18th October 2018” Cambridge, UK., 15 October 2018: Arecor Limited (“the […]
CATEGORY: Featured Friday, October 12, 2018 6:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten public offering of 16,537,500 […]
13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthetic valve endocarditis 83% (10 out of 12) patients in the modified intent-to-treat (mITT) population achieved treatment success […]
03 Oct 2018 Adherium (ASX:ADR), a leading digital health platform for medication adherence today announced its participation in the launch of the SmartAirLA program to empower communities to reduce the effects and prevalence of asthma in Los Angeles through Internet of Things technology. Using Adherium’s Hailie™ solution, SmartAirLA will help patients with asthma and COPD […]